55116-09-1

Basic information

• Product Name: 2-BROMOPHENYLACETYL CHLORIDE
• Synonyms: 2-Bromophenylacetyl chloride ,95%;2-(2-broMophenyl)acetyl chloride
• CAS NO: 55116-09-1
• Molecular Formula: C₈H₆BrClO
• Molecular Weight: 233.49
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 55116-09-1.mol

Chemical Properties

• Boiling Point: 186 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.57 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: n20/D 1.573(lit.)
• CAS DataBase Reference: 2-BROMOPHENYLACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOPHENYLACETYL CHLORIDE(55116-09-1)
• EPA Substance Registry System: 2-BROMOPHENYLACETYL CHLORIDE(55116-09-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 55116-09-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromophenylacetyl chloride is used as a synthetic intermediate for the production of various pharmaceuticals. It is employed to introduce the 2-bromophenylacetyl group into organic molecules, which can enhance the biological activity and therapeutic properties of the resulting compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Bromophenylacetyl chloride is used as a precursor in the synthesis of agrochemicals. It helps in the development of new pesticides and other agrochemical products by introducing the 2-bromophenylacetyl group, which can improve the effectiveness and selectivity of these compounds.
Used in Organic Synthesis:
2-Bromophenylacetyl chloride is used as a reactive acylating agent in organic synthesis. It is employed to introduce the 2-bromophenylacetyl group into a variety of organic molecules, which can alter their chemical properties and reactivity, leading to the formation of new compounds with potential applications in various fields.

InChI:InChI=1/C8H6BrClO/c9-7-4-2-1-3-6(7)5-8(10)11/h1-4H,5H2

Upstream product

• 4870-65-9 2-bromophenylacetic acid 
• 18698-97-0 ortho-bromophenylacetic acid 

Downstream Products

• 109558-14-7 β-(3,4-dimethoxyphenyl)ethyl-(2'-bromophenyl)acetamide 
• 139021-63-9 1-(2'-bromophenylacetyl)-1,2,5,6-tetrahydropyridine 
• 121989-40-0 2-(2-bromophenyl)-N-methoxyacetamide 
• 21906-31-0 1-(2-bromophenyl)propane-2-one 
• 65999-53-3 2-(2-bromophenyl)acetamide 
• 76016-35-8 N,N-dimethyl-o-bromophenylacetamide 
• 174533-57-4 4-Amino-3-[2-(2-bromo-phenyl)-acetylamino]-benzoic acid methyl ester 
• 196191-22-7 N-Benzyl-2-(2-bromophenyl)-N-(2,2-bis(phenylsulfanyl)ethenyl)acetamide 
• 339067-69-5 N-(2-{2-[(2-bromo-phenyl)-acetyl]-4,5-dimethoxy-phenyl}-ethyl)-acetamide 
• 406950-23-0 N-(2-benzoyl-4-nitrophenyl)-2-bromophenylacetic acid amide 
• 864445-60-3 JWH 249 
• 839673-85-7 2-(bromophenyl)-N-(2-phenylethyl)acetamide 
• 87201-30-7 N-<-2-(3,4-methylenedioxyphenyl)ethyl>-2'-bromophenylacetamide 
• 934355-42-7 2-(2-bromophenyl)-N-[2-(3-methoxyphenyl)ethyl]acetamide 

Relevant articles and documents

Facile and efficient route to prepare luminescent terbium containing covalently anchored hybrids equipped with molecular bridge

A kind of monomer (abbreviated as BrBAA-APES) was prepared by modifying 2-bromophenylacetic acid (BrBAA) with a coupling agent (3-aminopropyl) triethoxysilane (APES). Then it was used to coordinate to Tb3+ and to react with tetraethoxysilane (T

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

A Diverse Library of Chiral Cyclopropane Scaffolds via Chemoenzymatic Assembly and Diversification of Cyclopropyl Ketones

Chiral cyclopropane rings are key pharmacophores in pharmaceuticals and bioactive natural products, making libraries of these building blocks a valuable resource for drug discovery and development campaigns. Here, we report the development of a chemoenzymatic strategy for the stereoselective assembly and structural diversification of cyclopropyl ketones, a highly versatile yet underexploited class of functionalized cyclopropanes. An engineered variant of sperm whale myoglobin is shown to enable the highly diastereo- and enantioselective construction of these molecules via olefin cyclopropanation in the presence of a diazoketone carbene donor reagent. This biocatalyst offers a remarkably broad substrate scope, catalyzing this reaction with high stereoselectivity across a variety of vinylarene substrates as well as a range of different α-aryl and α-alkyl diazoketone derivatives. Chemical transformation of these enzymatic products enables further diversification of these molecules to yield a collection of structurally diverse cyclopropane-containing scaffolds in enantiopure form, including core motifs found in drugs and natural products as well as novel structures. This work illustrates the power of combining abiological biocatalysis with chemoenzymatic synthesis for generating collections of optically active scaffolds of high value for medicinal chemistry and drug discovery.

Quantitative activity-activity relationship (QAAR) driven design to develop hydroxamate derivatives of pentanoic acids as selective HDAC8 inhibitors: synthesis, biological evaluation and binding mode of interaction studies

Histone deacetylase 8 (HDAC8) has been implicated as a potential drug target of many diseases including cancer. HDAC8 isoform selectivity over other class-I HDACs is a major concern nowadays. In this work, a series of pentanoic acid based hydroxamates wit

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.

Palladium-Catalyzed 2-(Neopentylsulfinyl)aniline Directed C–H Acetoxylation and Alkenylation of Arylacetamides

The 2-(neopentylsulfinyl)aniline directing group that promotes rapid palladium-catalyzed C–H acetoxylation and alkenylation of arylacetamides has been developed. The acetoxylation reaches completion within only 40 min at 100 °C and leads to the bis-functionalized products. Alternatively, the reaction can be carried out at room temperature, which is beneficial for sensitive substrates. For the alkenylation, we have developed a protocol in which easily available 1-substituted cyclopropanols were employed as equivalents of vinyl ketones.

Parecoxib sodium substituted impurity and preparation method thereof

The invention relates to a parecoxib sodium substituted impurity and a preparation method thereof. The preparation method comprises the following steps: carrying out a reaction on a compound with a structure represented by a formula I with hydroxylamine h

Sequential Suzuki-Miyaura Coupling/Lewis Acid-Catalyzed Cyclization: An Entry to Functionalized Cycloalkane-Fused Naphthalenes

Functionalized angular cycloalkane-fused naphthalenes were prepared using a two-step process involving a Pd-catalyzed Suzuki-Miyaura coupling of aryl pinacol boronates and vinyl triflates followed by a boron trifluoride etherate-catalyzed cycloaromatization.

Resolution of Vaulted Biaryl Ligands via Borate Esters of Quinine and Quinidine

Given the sudden and unexplained rise in the cost of (+)- A nd (-)-sparteine, an alternative method for the resolution of vaulted biaryls has been developed. This method involves the reaction of a racemic vaulted biaryl ligand with one equivalent of BH3·SMe2 and one equivalent of either quinine or quinidine. A precipitate then forms from the resulting mixture of diastereomeric borates as a result of differential solubilities. Hydrolysis of the precipitate then liberates the (S)-ligand in the case of quinine and the (R)-ligand in the case of quinidine, both with >99% ee. This method has been applied to 16 different vaulted biaryl ligands, including 10 whose preparation is described here for the first time. In addition, proof of principle has been demonstrated for the dynamic thermodynamic resolution of the vaulted biaryl ligands with this method in combination with a nonchiral copper(II) complex that can racemize the ligand.

Macrolactam Synthesis via Ring-Closing Alkene-Alkene Cross-Coupling Reactions

Reported herein is a practical method for macrolactam synthesis via a Rh(III)-catalyzed ring closing alkene-alkene cross-coupling reaction. The reaction proceeded via a Rh-catalyzed alkenyl sp2 C-H activation process, which allows access to macrocyclic molecules of different ring sizes. Macrolactams containing a conjugated diene framework could be easily prepared in high chemoselectivities and Z,E stereoselectivities.